Stoquity Living researchResearch LedgerSlicesMethodologyFor institutionsAbout
Stoquity Research Ledger

Veracyte Inc. (VCYT)

NASDAQ: VCYT · Services-Medical Laboratories · South San Francisco, CA

Our rating: Positive

Positive reaffirmed at $46.41, moderate conviction, August 11, 2026.

Breaks if: Revenue growth rate falls below 10% year-over-year in two consecutive quarterly reports within the next twelve months — at that point the premium multiple loses its primary support and the call moves toward Cautious. On the upside, the call would upgrade toward Conviction if revenue growth sustains at or above 15% for three consecutive quarters while FCF margin expands to 28% or above, signaling that operating leverage is compounding alongside top-line durability.

Key figures

Market value$2.0B
Revenue, last 12 months$582M
Net income, last 12 months$127M
Free cash flow, last 12 months$162M
Price to earnings16.0×
Free cash flow yield8.0%
Dividend yield0.0%
Operating margin17.1%
Return on equity9.4%
Beta to the S&P 5001.66
Volatility, annualized68.1%

Reported quarters

Quarter endingRevenueYear on yearEarnings per shareFree cash flow
September 30, 2026$152M15.1%$0.38$38M
June 30, 2026$150M15.5%$0.31$43M
March 31, 2026$139M21.5%$0.35$32M
December 31, 2025$141M18.5%$0.50$49M
September 30, 2025$132M13.8%$0.24$42M
June 30, 2025$130M13.8%$-0.01$32M
March 31, 2025$114M18.2%$0.09$4M
December 31, 2024$119M20.8%$0.06$20M

Three-model forecasts for the next quarter

Written November 21, 2026, before the report. Each settles from the SEC filing.

13 ledger entries and 53 corporate events on record. Share price as of November 20, 2026. Research and education only. Not investment advice. Stoquity does not manage money or know your circumstances. Ratings, forecasts and lists are produced by software and AI models and can be wrong. Performance figures are hypothetical, measured on paper against a benchmark, and say nothing certain about the future.